Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Actinium Ac 225-DOTA-Daratumumab

A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, conjugated to the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-DOTA-daratumumab, the monoclonal antibody moiety specifically targets and binds to cell surface antigen CD38. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to CD38-expressing tumor cells. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[225Ac]-DOTA-daratumumab
225Ac-DOTA-daratumumab
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search